Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Enliven s loss grows as drug trials progress – BizWest bizwest.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizwest.com Daily Mail and Mail on Sunday newspapers.
Enliven Therapeutics’ reverse merger with Imara will form a combined company with $300 million to finance clinical development of new cancer drugs. Its most advanced program is a tyrosine kinase inhibitor for chronic myeloid leukemia.
Concurrent with the merger, Enliven plans to raise $165 million in a private financing, and the joint company is expected to have $300 million in cash and cash equivalents.